BioNTech’s Bold Leap Beyond COVID: Navigating Losses and Pioneering Cancer Treatments
BioNTech faces a revenue decline, with earnings per share dropping from €1.90 to €1.08, yet surpassing market expectations of €0.407. Total revenue decreased from €3.82 billion to €2.75 billion, transitioning…